Thermo Fisher Scientific (TMO)
(Delayed Data from NYSE)
$513.08 USD
-19.94 (-3.74%)
Updated Nov 15, 2024 04:00 PM ET
After-Market: $514.00 +0.92 (0.18%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$513.08 USD
-19.94 (-3.74%)
Updated Nov 15, 2024 04:00 PM ET
After-Market: $514.00 +0.92 (0.18%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth D Momentum D VGM
Zacks News
Thermo Fisher (TMO) Beats on Q3 Earnings, Lifts Guidance
by Zacks Equity Research
We are encouraged that three out of Thermo Fisher's (TMO) four business segments have registered strong year-over-year revenue growth in Q3.
Thermo Fisher Scientific (TMO) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Thermo Fisher (TMO) delivered earnings and revenue surprises of 2.08% and 1.33%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Medical Products' Earnings Roster for Oct 23: TMO, BSX & More
by Zacks Equity Research
Encouraging growth in the emerging markets despite the ongoing trade tiff is likely to contribute to revenues in the medical products space this earnings season.
What's in Store for Thermo Fisher (TMO) in Q3 Earnings?
by Zacks Equity Research
Developments in business segments are likely to have aided Thermo Fisher (TMO) in the third quarter.
Thermo Fisher Scientific (TMO) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Thermo Fisher (TMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Thermo Fisher Scientific (TMO) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (TMO) Outperforming Other Medical Stocks This Year?
Thermo Fisher Gets a Boost from Buyouts and Global Expansion
by Urmimala Biswas
Thermo Fisher (TMO) registers a solid international performance with strong growth in Europe and Asia-Pacific including China.
The Zacks Analyst Blog Highlights: Microsoft, Royal Dutch, IBM, Thermo Fisher and American Tower
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Microsoft, Royal Dutch, IBM, Thermo Fisher and American Tower
Top Stock Reports for Microsoft, Royal Dutch Shell & IBM
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Microsoft (MSFT), Royal Dutch Shell (RDS.A) and IBM (IBM).
Thermo Fisher Closes API Site Buyout, Fortifies Pharma Unit
by Zacks Equity Research
Following the acquisition closure of GlaxoSmithKline's plant, Thermo Fisher (TMO) will continue to manufacture APIs for the same under a multi-year supply agreement.
Here's Why You Should Add Thermo Fisher to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Thermo Fisher's (TMO) performance.
Zacks.com featured highlights include: Booz Allen Hamilton, Thermo Fisher Scientific, Target, Microsoft and Barrel Old Country Store
by Zacks Equity Research
Zacks.com featured highlights include: Booz Allen Hamilton, Thermo Fisher Scientific, Target, Microsoft and Barrel Old Country Store
7 Dividend Growth Stocks to Buy for October
by Sweta Killa
Dividend-paying securities are a major source of consistent income for investors when returns from the equity market are at risk.
Roper (ROP) Agrees to Sell Gatan to AMETEK for $925M in Cash
by Zacks Equity Research
Roper's (ROP) Gatan divestment, to be completed in the fourth quarter of 2019, will help it concentrate on its core and profitable businesses.
Is Thermo Fisher Scientific (TMO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (TMO) Outperforming Other Medical Stocks This Year?
4 Stocks to Focus on Global Biotechnology Reagents Market
by Zacks Equity Research
Increased use of reagents in the field of research, bioscience and genetics is pushing the biotechnology reagents market higher.
The Zacks Analyst Blog Highlights: AT&T, Thermo Fisher, Schwab, Veeva and PVH
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AT&T, Thermo Fisher, Schwab, Veeva and PVH
Here's Why You Should Hold on to Thermo Fisher (TMO) for Now
by Zacks Equity Research
Investors continue to be optimistic about Thermo Fisher's (TMO) performance.
Top Stock Reports for AT&T, Thermo Fisher & Schwab
by Mark Vickery
Today's Research Daily features updated research reports on 16 major stocks, including AT&T (T), Thermo Fisher (TMO) and Schwab (SCHW).
Semtech (SMTC) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Semtech's (SMTC) fiscal second-quarter results may be affected by China demand softness and competition. However, differentiated growth drivers and diversification might aid its earnings.
Thermo Fisher (TMO) Down 4.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
What's in the Cards for AMETEK (AME) This Earnings Season?
by Zacks Equity Research
AMETEK's (AME) Q2 earnings are likely to be driven by strong organic growth and contributions from acquisitions. Yet, ongoing trade tensions might affect its upcoming results.
What's in the Cards for Expedia Group's (EXPE) Q2 Earnings?
by Zacks Equity Research
Strength across segments is likely to drive Expedia Group's (EXPE) second-quarter revenues.
The Zacks Analyst Blog Highlights: Comcast, Thermo Fisher, McDonald's, Canadian National and NextEra
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Comcast, Thermo Fisher, McDonald's, Canadian National and NextEra
Thermo Fisher (TMO) Beats on Q2 Earnings, Lifts Guidance
by Zacks Equity Research
Banking on a strong operational performance, Thermo Fisher (TMO) raises its 2019 revenue and earnings guidance.